BIO-B
Bio-Rad Laboratories, Inc.
Price Chart
Latest Quote
$304.15
+0.00 (+0.00%)
Current Price
| Previous Close | $304.15 |
| Open | $304.15 |
| Day High | $304.15 |
| Day Low | $304.15 |
| Volume | 13 |
Stock Information
| Shares Outstanding | 5.06M |
| Total Debt | $1.38B |
| Cash Equivalents | $1.56B |
| Revenue | $2.59B |
| Net Income | $168.80M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $8.14B |
| P/E Ratio | 50.52 |
| EPS (TTM) | $6.02 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.95B |
| Sales | $2.59B |
| Income | $168.80M |
| Book/sh | $255.37 |
| Cash/sh | $309.17 |
| Employees | 7K |
Financial Ratios
| Quick Ratio | 2.19 |
| Current Ratio | 3.21 |
| Debt/Eq | 20.12 |
Returns & Margins
| ROA | 1.79% |
| ROE | 2.50% |
| Gross Margin | 52.01% |
| Operating Margin | 5.76% |
| Profit Margin | 6.52% |
Ownership
| Insider Ownership | 98.23% |
| Institutional Ownership | 0.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 4.23 |
| P/S | 3.14 |
| P/B | 1.19 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $276.90 |
| SMA50 | $279.74 |
| SMA200 | $286.86 |
| RSI | 100.00 |
| ATR | 3.6443 |
| Shares Float | 20.90M |
| Short Float | 0.01% |
| Short Ratio | 0.16 |
| Volatility | 1.08 |
Performance History
| Week | +0.00% |
| Month | +17.68% |
| Quarter | +7.87% |
| 6 Months | -2.11% |
| YTD | -2.11% |
| Year | +21.62% |
| 3 Years | -18.65% |
| 5 Years | -49.03% |
| 10 Years | +104.07% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $304.15 | 0 |
| 2026-06-03 | $304.15 | 0 |
| 2026-06-02 | $304.15 | 0 |
| 2026-06-01 | $304.15 | 0 |
| 2026-05-29 | $304.15 | 0 |
| 2026-05-28 | $304.15 | 0 |
| 2026-05-27 | $304.15 | 100 |
| 2026-05-26 | $267.43 | 0 |
| 2026-05-22 | $267.43 | 0 |
| 2026-05-21 | $267.43 | 0 |
| 2026-05-20 | $267.43 | 0 |
| 2026-05-19 | $267.43 | 0 |
| 2026-05-18 | $267.43 | 100 |
| 2026-05-15 | $260.90 | 600 |
| 2026-05-14 | $260.00 | 3,400 |
| 2026-05-13 | $255.54 | 0 |
| 2026-05-12 | $255.54 | 0 |
| 2026-05-11 | $255.54 | 0 |
| 2026-05-08 | $255.54 | 400 |
| 2026-05-07 | $261.27 | 0 |
| 2026-05-06 | $261.27 | 100 |
| 2026-05-05 | $258.46 | 900 |
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
đ° Latest News
Is Elliottâs Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?
Simply Wall St. âĸ 2026-05-25T11:11:24Z
Elliott Targets Bio-Rad After 70% Stock Collapse
GuruFocus.com âĸ 2026-05-22T17:25:32ZSector Update: Healthcare Stocks Decline Pre-Bell Monday
MT Newswires âĸ 2026-05-18T13:18:50ZActivist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
The Wall Street Journal âĸ 2026-05-18T00:03:00Z
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out
Insider Monkey âĸ 2026-05-05T16:14:44Z
How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions
Simply Wall St. âĸ 2026-05-04T18:12:38Z
Bio-Rad (BIO) Q2 2025 Earnings Call Transcript
Motley Fool âĸ 2026-05-04T14:27:20Z
Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects
Zacks âĸ 2026-05-04T13:15:08Z
Bio-Rad (BIO) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-01T16:28:28Z
Bio-Rad Laboratories, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-01T12:30:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,187,600,000 | $1,244,300,000 | $1,234,900,000 | $1,284,449,000 |
| Cost Of Revenue | $1,187,600,000 | $1,244,300,000 | $1,234,900,000 | $1,284,449,000 |
| Total Revenue | $2,566,500,000 | $2,671,200,000 | $2,802,200,000 | $2,922,545,000 |
| Operating Revenue | $2,566,500,000 | $2,671,200,000 | $2,802,200,000 | $2,922,545,000 |
| Expenses | ||||
| Interest Expense | $48,900,000 | $49,400,000 | $38,100,000 | $1,551,000 |
| Total Expenses | $2,297,500,000 | $2,333,400,000 | $2,327,100,000 | $2,422,209,000 |
| Other Income Expense | $-2,644,600,000 | $-1,239,400,000 | $-5,199,300,000 | $4,931,395,000 |
| Other Non Operating Income Expenses | $1,600,000 | $2,400,000 | $2,300,000 | $700,000 |
| Net Non Operating Interest Income Expense | $33,100,000 | $51,500,000 | $20,000,000 | $17,349,000 |
| Interest Expense Non Operating | $48,900,000 | $49,400,000 | $38,100,000 | $1,551,000 |
| Operating Expense | $1,109,900,000 | $1,089,100,000 | $1,092,200,000 | $1,137,760,000 |
| Other Operating Expenses | - | - | $7,500,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Net Interest Income | $33,100,000 | $51,500,000 | $20,000,000 | $17,349,000 |
| Interest Income | $82,000,000 | $100,900,000 | $58,100,000 | $18,900,000 |
| Normalized Income | $238,359,400 | $294,050,000 | $382,933,600 | $403,384,205 |
| Net Income From Continuing And Discontinued Operation | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Total Operating Income As Reported | $269,000,000 | $337,800,000 | $482,600,000 | $500,336,000 |
| Net Income Common Stockholders | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Net Income | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Net Income Including Noncontrolling Interests | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Net Income Continuous Operations | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Pretax Income | $-2,342,500,000 | $-850,100,000 | $-4,704,200,000 | $5,449,055,000 |
| Special Income Charges | $0 | $2,500,000 | $-10,500,000 | $-800,000 |
| Interest Income Non Operating | $82,000,000 | $100,900,000 | $58,100,000 | $18,900,000 |
| Operating Income | $269,000,000 | $337,800,000 | $475,100,000 | $500,336,000 |
| Gross Profit | $1,378,900,000 | $1,426,900,000 | $1,567,300,000 | $1,638,096,000 |
| Per Share | ||||
| Diluted EPS | $-65.36 | $-21.82 | $-121.79 | $140.56 |
| Basic EPS | $-65.36 | $-21.82 | $-121.79 | $142.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $-563,640,600 | $-310,450,000 | $-1,191,166,400 | $1,079,822,205 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $504,200,000 | $587,000,000 | $672,800,000 | $657,511,000 |
| Total Unusual Items | $-2,646,200,000 | $-1,241,800,000 | $-5,201,600,000 | $4,930,695,000 |
| Total Unusual Items Excluding Goodwill | $-2,646,200,000 | $-1,241,800,000 | $-5,201,600,000 | $4,930,695,000 |
| Reconciled Depreciation | $151,600,000 | $145,900,000 | $137,300,000 | $137,600,000 |
| EBITDA (Bullshit earnings) | $-2,142,000,000 | $-654,800,000 | $-4,528,800,000 | $5,588,206,000 |
| EBIT | $-2,293,600,000 | $-800,700,000 | $-4,666,100,000 | $5,450,606,000 |
| Diluted Average Shares | $28,214,000 | $29,209,000 | $29,785,000 | $30,208,000 |
| Basic Average Shares | $28,214,000 | $29,209,000 | $29,785,000 | $29,831,000 |
| Diluted NI Availto Com Stockholders | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,257,000 |
| Tax Provision | $-498,300,000 | $-212,800,000 | $-1,076,700,000 | $1,194,798,000 |
| Gain On Sale Of Business | $0 | $0 | $1,400,000 | $0 |
| Write Off | $0 | $0 | $11,900,000 | $800,000 |
| Gain On Sale Of Security | $-2,646,200,000 | $-1,244,300,000 | $-5,191,100,000 | $4,931,495,000 |
| Provision For Doubtful Accounts | $0 | $0 | $7,500,000 | $0 |
| Research And Development | $295,900,000 | $247,400,000 | $256,900,000 | $260,638,000 |
| Selling General And Administration | $814,000,000 | $841,700,000 | $827,800,000 | $877,122,000 |
| Other Special Charges | - | $-2,500,000 | - | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,865,200,000 | $8,007,100,000 | $8,876,652,000 | $13,084,036,000 |
| Total Assets | $9,364,100,000 | $12,299,100,000 | $13,501,666,000 | $17,799,393,000 |
| Total Non Current Assets | $6,333,800,000 | $9,250,800,000 | $10,343,643,000 | $15,808,832,000 |
| Other Non Current Assets | $101,900,000 | $94,900,000 | $94,599,000 | $104,189,000 |
| Goodwill And Other Intangible Assets | $704,100,000 | $734,100,000 | $738,600,000 | $601,200,000 |
| Other Intangible Assets | $293,600,000 | $320,500,000 | $332,100,000 | $253,900,000 |
| Current Assets | $3,030,300,000 | $3,048,300,000 | $3,157,976,000 | $1,990,479,000 |
| Other Current Assets | $30,700,000 | $26,100,000 | $23,604,000 | $10,089,000 |
| Restricted Cash | $0 | $5,600,000 | $5,560,000 | $5,560,000 |
| Prepaid Assets | $122,600,000 | $140,000,000 | $124,179,000 | $109,136,000 |
| Inventory | $760,000,000 | $780,500,000 | $719,316,000 | $572,239,000 |
| Receivables | $452,500,000 | $489,000,000 | $494,645,000 | $423,537,000 |
| Accounts Receivable | $452,500,000 | $489,000,000 | $494,645,000 | $423,537,000 |
| Allowance For Doubtful Accounts Receivable | $-9,200,000 | $-14,900,000 | $-15,029,000 | $-15,142,000 |
| Gross Accounts Receivable | $461,700,000 | $503,900,000 | $509,674,000 | $438,679,000 |
| Cash Cash Equivalents And Short Term Investments | $1,664,500,000 | $1,607,100,000 | $1,790,672,000 | $869,918,000 |
| Cash And Cash Equivalents | $488,100,000 | $403,800,000 | $434,215,000 | $470,783,000 |
| Debt | ||||
| Net Debt | $713,500,000 | $795,800,000 | $763,950,000 | - |
| Total Debt | $1,374,700,000 | $1,405,500,000 | $1,388,098,000 | $223,376,000 |
| Long Term Debt And Capital Lease Obligation | $1,331,800,000 | $1,364,600,000 | $1,351,297,000 | $186,452,000 |
| Long Term Debt | $1,200,400,000 | $1,199,100,000 | $1,197,700,000 | $10,514,000 |
| Current Debt And Capital Lease Obligation | $42,900,000 | $40,900,000 | $36,801,000 | $36,924,000 |
| Current Debt | $1,200,000 | $500,000 | $465,000 | $489,000 |
| Other Current Borrowings | $1,200,000 | $500,000 | $465,000 | $489,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,794,800,000 | $3,557,900,000 | $3,886,414,000 | $4,114,157,000 |
| Total Non Current Liabilities Net Minority Interest | $2,327,000,000 | $3,035,100,000 | $3,317,706,000 | $3,433,219,000 |
| Other Non Current Liabilities | $177,200,000 | $195,000,000 | $195,928,000 | $182,191,000 |
| Non Current Deferred Liabilities | $818,000,000 | $1,475,500,000 | $1,770,481,000 | $3,064,576,000 |
| Non Current Deferred Taxes Liabilities | $818,000,000 | $1,475,500,000 | $1,770,481,000 | $3,064,576,000 |
| Current Liabilities | $467,800,000 | $522,800,000 | $568,708,000 | $680,938,000 |
| Other Current Liabilities | $147,200,000 | $161,600,000 | $169,648,000 | $127,936,000 |
| Payables And Accrued Expenses | $277,700,000 | $320,300,000 | $362,259,000 | $465,226,000 |
| Payables | $153,500,000 | $180,400,000 | $167,469,000 | $188,240,000 |
| Total Tax Payable | $31,200,000 | $35,800,000 | $32,428,000 | $46,299,000 |
| Accounts Payable | $122,300,000 | $144,600,000 | $135,041,000 | $141,941,000 |
| Current Deferred Liabilities | - | - | $52,211,000 | $50,852,000 |
| Income Tax Payable | - | - | $11,929,000 | $10,319,000 |
| Equity | ||||
| Common Stock Equity | $6,569,300,000 | $8,741,200,000 | $9,615,252,000 | $13,685,236,000 |
| Total Equity Gross Minority Interest | $6,569,300,000 | $8,741,200,000 | $9,615,252,000 | $13,685,236,000 |
| Stockholders Equity | $6,569,300,000 | $8,741,200,000 | $9,615,252,000 | $13,685,236,000 |
| Gains Losses Not Affecting Retained Earnings | $-538,200,000 | $-336,000,000 | $-466,822,000 | $-175,553,000 |
| Other Equity Adjustments | $-538,200,000 | $-336,000,000 | $-466,822,000 | $-175,553,000 |
| Retained Earnings | $7,416,400,000 | $9,260,600,000 | $9,898,203,000 | $13,525,343,000 |
| Other | ||||
| Treasury Shares Number | $2,254,728 | $1,747,438 | $640,492 | $279,544 |
| Ordinary Shares Number | $28,011,144 | $28,518,436 | $29,595,713 | $29,932,438 |
| Share Issued | $30,265,872 | $30,265,874 | $30,236,205 | $30,211,982 |
| Tangible Book Value | $5,865,200,000 | $8,007,100,000 | $8,876,652,000 | $13,084,036,000 |
| Invested Capital | $7,770,900,000 | $9,940,800,000 | $10,813,417,000 | $13,696,239,000 |
| Working Capital | $2,562,500,000 | $2,525,500,000 | $2,589,268,000 | $1,309,541,000 |
| Capital Lease Obligations | $173,100,000 | $205,900,000 | $189,933,000 | $212,373,000 |
| Total Capitalization | $7,769,700,000 | $9,940,300,000 | $10,812,952,000 | $13,695,750,000 |
| Treasury Stock | $772,100,000 | $632,500,000 | $263,586,000 | $106,290,000 |
| Additional Paid In Capital | $463,200,000 | $449,100,000 | $447,454,000 | $441,733,000 |
| Capital Stock | $0 | $0 | $3,000 | $3,000 |
| Common Stock | $0 | $0 | $3,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $131,400,000 | $165,500,000 | $153,597,000 | $175,938,000 |
| Current Capital Lease Obligation | $41,700,000 | $40,400,000 | $36,336,000 | $36,435,000 |
| Current Accrued Expenses | $124,200,000 | $139,900,000 | $194,790,000 | $276,986,000 |
| Investments And Advances | $4,839,200,000 | $7,698,100,000 | $8,830,892,000 | $14,387,006,000 |
| Other Investments | $4,839,200,000 | $7,698,100,000 | $8,830,892,000 | $14,387,006,000 |
| Goodwill | $410,500,000 | $413,600,000 | $406,500,000 | $347,300,000 |
| Net PPE | $688,600,000 | $723,700,000 | $679,552,000 | $716,437,000 |
| Accumulated Depreciation | $-1,109,200,000 | $-1,066,700,000 | $-1,009,400,000 | $-1,001,840,000 |
| Gross PPE | $1,797,800,000 | $1,790,400,000 | $1,688,952,000 | $1,718,277,000 |
| Other Properties | $1,343,700,000 | $1,342,200,000 | $1,267,552,000 | $1,304,539,000 |
| Buildings And Improvements | $426,300,000 | $419,800,000 | $393,600,000 | $385,798,000 |
| Land And Improvements | $27,800,000 | $28,400,000 | $27,800,000 | $27,940,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $294,800,000 | $302,900,000 | $269,600,000 | $257,300,000 |
| Work In Process | $243,200,000 | $246,000,000 | $220,900,000 | $198,000,000 |
| Raw Materials | $222,000,000 | $231,600,000 | $228,800,000 | $116,900,000 |
| Other Short Term Investments | $1,176,400,000 | $1,203,300,000 | $1,356,457,000 | $399,135,000 |
| Other Inventories | - | $17,000 | $16,000 | $39,000 |
| Current Deferred Revenue | - | - | $52,211,000 | $50,852,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $266,200,000 | $218,200,000 | $80,100,000 | $535,718,000 |
| Operating Activities | ||||
| Operating Cash Flow | $455,200,000 | $374,900,000 | $194,400,000 | $669,464,000 |
| Cash Flow From Continuing Operating Activities | $455,200,000 | $374,900,000 | $194,400,000 | $669,500,000 |
| Operating Gains Losses | - | $-2,500,000 | $-1,400,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-189,000,000 | $-156,700,000 | $-114,300,000 | $-133,746,000 |
| Investing Cash Flow | $-160,200,000 | $20,200,000 | $-1,207,600,000 | $-797,381,000 |
| Cash Flow From Continuing Investing Activities | $-160,200,000 | $20,200,000 | $-1,207,600,000 | $-797,381,000 |
| Net Other Investing Changes | - | - | - | $-453,440,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-203,600,000 | $-428,700,000 | $-215,700,000 | $-49,998,000 |
| Financing Cash Flow | $-218,800,000 | $-425,600,000 | $973,600,000 | $-55,429,000 |
| Cash Flow From Continuing Financing Activities | $-218,800,000 | $-425,600,000 | $973,600,000 | $-55,429,000 |
| Net Other Financing Charges | $-34,000,000 | $-14,900,000 | $-14,000,000 | $-23,043,000 |
| Net Common Stock Issuance | $-203,600,000 | $-428,700,000 | $-215,700,000 | $-49,998,000 |
| Other | ||||
| Repayment Of Debt | $-400,000 | $-500,000 | $-500,000 | $-3,020,000 |
| Issuance Of Debt | $0 | $0 | $1,186,200,000 | $0 |
| End Cash Position | $489,800,000 | $404,400,000 | $434,500,000 | $471,133,000 |
| Beginning Cash Position | $404,400,000 | $434,500,000 | $471,100,000 | $667,115,000 |
| Effect Of Exchange Rate Changes | $9,200,000 | $400,000 | $3,000,000 | $-12,636,000 |
| Changes In Cash | $76,200,000 | $-30,500,000 | $-39,600,000 | $-183,346,000 |
| Proceeds From Stock Option Exercised | $19,200,000 | $18,500,000 | $17,600,000 | $20,632,000 |
| Common Stock Payments | $-203,600,000 | $-428,700,000 | $-215,700,000 | $-49,998,000 |
| Net Issuance Payments Of Debt | $-400,000 | $-500,000 | $1,185,700,000 | $-3,020,000 |
| Net Long Term Debt Issuance | $-400,000 | $-500,000 | $1,185,700,000 | $-3,020,000 |
| Long Term Debt Payments | $-400,000 | $-500,000 | $-500,000 | $-3,020,000 |
| Long Term Debt Issuance | $0 | $0 | $1,186,200,000 | $0 |
| Net Investment Purchase And Sale | $28,700,000 | $174,200,000 | $-994,200,000 | $-84,731,000 |
| Sale Of Investment | $1,305,300,000 | $863,200,000 | $1,066,000,000 | $766,896,000 |
| Purchase Of Investment | $-1,276,600,000 | $-689,000,000 | $-2,060,200,000 | $-851,627,000 |
| Net Business Purchase And Sale | $0 | $2,500,000 | $-99,300,000 | $-125,516,000 |
| Sale Of Business | $0 | $2,500,000 | $1,400,000 | $0 |
| Purchase Of Business | $0 | $0 | $-100,700,000 | $-125,516,000 |
| Net Intangibles Purchase And Sale | $-23,400,000 | $0 | $-1,500,000 | $0 |
| Purchase Of Intangibles | $-23,400,000 | $0 | $-1,500,000 | $0 |
| Net PPE Purchase And Sale | $-165,500,000 | $-156,500,000 | $-112,600,000 | $-133,694,000 |
| Sale Of PPE | $100,000 | $200,000 | $200,000 | $52,000 |
| Purchase Of PPE | $-165,600,000 | $-156,700,000 | $-112,800,000 | $-133,746,000 |
| Change In Working Capital | $-620,800,000 | $-432,800,000 | $-1,610,000,000 | $1,143,100,000 |
| Change In Other Working Capital | $-626,800,000 | $-322,600,000 | $-1,241,600,000 | $1,084,900,000 |
| Change In Other Current Liabilities | $5,600,000 | $-4,100,000 | $5,600,000 | $10,500,000 |
| Change In Other Current Assets | $-7,500,000 | $1,900,000 | $-32,400,000 | $-19,100,000 |
| Change In Payables And Accrued Expense | $-16,800,000 | $-73,100,000 | $-95,400,000 | $41,100,000 |
| Change In Payable | $-16,800,000 | $-73,100,000 | $-95,400,000 | $41,100,000 |
| Change In Account Payable | $-40,900,000 | $-51,800,000 | $-94,200,000 | $69,900,000 |
| Change In Tax Payable | $24,100,000 | $-21,300,000 | $-1,200,000 | $-28,800,000 |
| Change In Income Tax Payable | $24,100,000 | $-21,300,000 | $-1,200,000 | $-28,800,000 |
| Change In Inventory | $8,500,000 | $-46,300,000 | $-158,800,000 | $46,100,000 |
| Change In Receivables | $16,200,000 | $11,400,000 | $-87,400,000 | $-20,400,000 |
| Changes In Account Receivables | $16,200,000 | $11,400,000 | $-87,400,000 | $-20,400,000 |
| Other Non Cash Items | $49,500,000 | $-12,000,000 | $22,100,000 | $8,664,000 |
| Stock Based Compensation | $62,300,000 | $61,300,000 | $60,900,000 | $51,200,000 |
| Unrealized Gain Loss On Investment Securities | $2,656,800,000 | $1,252,300,000 | $5,193,600,000 | $-4,926,200,000 |
| Provisionand Write Offof Assets | $0 | $0 | $7,500,000 | $0 |
| Asset Impairment Charge | $0 | $0 | $11,900,000 | $800,000 |
| Depreciation Amortization Depletion | $151,600,000 | $145,900,000 | $137,300,000 | $137,600,000 |
| Depreciation And Amortization | $151,600,000 | $145,900,000 | $137,300,000 | $137,600,000 |
| Gain Loss On Sale Of Business | $0 | $-2,500,000 | $-1,400,000 | $0 |
| Net Income From Continuing Operations | $-1,844,200,000 | $-637,300,000 | $-3,627,500,000 | $4,254,300,000 |
Fetched: 2026-02-02